Kymera’s KT-621 shows promise in preclinical asthma study

WATERTOWN, Mass. - Kymera Therapeutics, Inc. (NASDAQ: KYMR), a $1.94 billion market cap biotech company with a strong balance sheet showing more cash than debt, has announced promising preclinical data for its oral STAT6 degrader, KT-621, which has demonstrated activity comparable or superior to dupilumab in a chronic asthma model. This potential new treatment for asthma and other Th2 allergic and atopic diseases was presented at the American Thoracic Society International Conference. According to InvestingPro data, the company maintains excellent liquidity with a current ratio of 8.49, providing solid financial backing for its development programs.

The preclinical data suggest that KT-621 could be effective in both preventing and reversing disease progression in a mouse model. These findings may position KT-621 as a convenient once-daily oral medication for conditions with limited treatment options. The market appears optimistic about these developments, with 8 analysts recently revising their earnings expectations upward, according to InvestingPro analysis. Kymera’s Chief Medical Officer, Jared Gollob, MD, highlighted the potential of KT-621 during an oral presentation at the conference.

Kymera has completed a Phase 1 trial with healthy volunteers to assess KT-621’s safety and tolerability, with full data expected to be released in June 2025. The company is also conducting the BroADen Phase 1b trial in patients with moderate to severe atopic dermatitis, with results anticipated in the fourth quarter of 2025. Plans are underway to initiate two parallel Phase 2b trials in atopic dermatitis and asthma towards the end of 2025 and the beginning of 2026, respectively.

KT-621 is the first STAT6 targeted medicine to enter clinical development and has shown potential in preclinical studies to mimic the activity of injectable biologics like dupilumab. The medication is designed to degrade STAT6, a transcription factor central to Th2 inflammation, which is implicated in various conditions, including asthma and atopic dermatitis.

As a clinical-stage biotechnology firm, Kymera is at the forefront of developing targeted protein degradation therapies. The company aims to bring new oral small molecule degraders to market, offering patients convenient and effective treatments for immunological diseases. While currently pre-profit, the company’s strong financial health score and robust cash position suggest solid execution potential. For deeper insights into Kymera’s financial metrics and growth prospects, investors can access the comprehensive Pro Research Report available on InvestingPro, which covers over 1,400 US stocks with detailed analysis and actionable intelligence.

In other recent news, Kymera Therapeutics reported a narrower-than-expected loss for the first quarter of 2025, with an EPS of -0.82 compared to the forecast of -0.89. The company’s revenue also exceeded expectations, reaching $22.1 million against the projected $11.38 million. Truist Securities maintained a Buy rating for Kymera Therapeutics, keeping the price target at $53.00, following the company’s first-quarter results. BTIG analyst Jeet Mukherjee adjusted the price target for Kymera Therapeutics to $55.00 from the previous $60.00, while reiterating a Buy rating on the stock.

Kymera Therapeutics introduced KT-579, an oral IRF5 degrader targeting inflammatory diseases, and decided to discontinue the development of its TYK2 degrader program. This strategic move is expected to extend the company’s cash runway into the first half of 2028. Truist Securities expressed optimism about the potential of KT-579 to complement existing treatments for inflammatory and autoimmune conditions. The focus for the near term remains on KT-621, with high-value data anticipated to be released in June. Analysts from both Truist and BTIG see potential in Kymera’s pipeline expansion and strategic refocusing.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.